CLSN - Celsion Corporation
1.9300 +0.03 (1.58%)
After hours: 7:46PM EDT
| Previous Close | 1.9000 |
| Open | 1.8900 |
| Bid | 1.5900 x 1200 |
| Ask | 1.9300 x 4000 |
| Day's Range | 1.8600 - 1.9000 |
| 52 Week Range | 1.3500 - 3.1000 |
| Volume | 91,732 |
| Avg. Volume | 98,446 |
| Market Cap | 42.657M |
| Beta (3Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT
Q2 2019 Celsion Corp Earnings Call
- Zacks
Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Before You Buy Celsion Corporation (NASDAQ:CLSN), Consider Its Volatility
If you own shares in Celsion Corporation (NASDAQ:CLSN) then it's worth thinking about how it contributes to the...
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT
Q1 2019 Celsion Corp Earnings Call
- Zacks
Is Celsion (CLSN) Stock Outpacing Its Medical Peers This Year?
Is (CLSN) Outperforming Other Medical Stocks This Year?
- Zacks
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.
- Zacks
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
- Zacks
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
- Zacks
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
- Zacks
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
- Zacks
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
- Zacks
Will Celsion (CLSN) Report Negative Earnings Next Week? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Celsion (CLSN) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Celsion (CLSN) closed at $2.19, marking a -1.79% move from the previous day.
- Zacks
Celsion (CLSN) Flat As Market Sinks: What You Should Know
Celsion (CLSN) closed at $2.20 in the latest trading session, marking no change from the prior day.
- Zacks
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
- Zacks
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
- Zacks
Is Celsion (CLSN) Outperforming Other Medical Stocks This Year?
Is (CLSN) Outperforming Other Medical Stocks This Year?
- Zacks
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
- Zacks
Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
- Zacks
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 29-Mar-19 3:00pm GMT
Full Year 2018 Celsion Corp Earnings Call
- Zacks
Celsion (CLSN) Moves to Strong Buy: Rationale Behind the Upgrade
Celsion (CLSN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-Nov-18 4:00pm GMT
Q3 2018 Celsion Corp Earnings Call
GuruFocus.comAnalysts Take Action on Health Care Stocks
The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday. The share price has increased 46% over the 52 weeks of trading through Nov. 20. Warning! GuruFocus has detected 6 Warning Signs with BGNE.
- Benzinga
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
